MX9701529A - Uso de (e)-1-[4'-(2-alquilaminoetoxi)fenil]-1-(3'-hidroxifenil)-2-f enilbut-1-enos para inhibir trastornos patologicos. - Google Patents

Uso de (e)-1-[4'-(2-alquilaminoetoxi)fenil]-1-(3'-hidroxifenil)-2-f enilbut-1-enos para inhibir trastornos patologicos.

Info

Publication number
MX9701529A
MX9701529A MX9701529A MX9701529A MX9701529A MX 9701529 A MX9701529 A MX 9701529A MX 9701529 A MX9701529 A MX 9701529A MX 9701529 A MX9701529 A MX 9701529A MX 9701529 A MX9701529 A MX 9701529A
Authority
MX
Mexico
Prior art keywords
triphenylbut
alzheimers disease
ene derivatives
treating alzheimers
methyl
Prior art date
Application number
MX9701529A
Other languages
English (en)
Other versions
MXPA97001529A (es
Inventor
David Burton Maclean
David Duane Thompson
Original Assignee
Pfizer
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer filed Critical Pfizer
Publication of MX9701529A publication Critical patent/MX9701529A/es
Publication of MXPA97001529A publication Critical patent/MXPA97001529A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/138—Aryloxyalkylamines, e.g. propranolol, tamoxifen, phenoxybenzamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Abstract

La presente invencion proporciona el uso de un compuesto de formula I en la que R1 y R2 pueden ser iguales o diferentes, a condicion de que, cuando R1 y R2 son iguales, cada uno es un grupo metilo o etilo, y, cuando R1 y R2 son diferentes, uno de ellos es un grupo metilo o etilo y el otro es hidrogeno o un grupo bencilo; o una de sus sales farmacéuticamente aceptables, en la preparacion de composiciones para inhibir trastornos patologicos relacionados con sistemas de organos que responden a los agonistas de estrogeno en un mamífero en necesidad de dicho tratamiento.
MXPA/A/1997/001529A 1996-02-28 1997-02-27 Uso de (e)-1-[4'-(2-alquilaminoetoxi)fenil]-1-(3'-hidroxifenil)-2-fenilbut-1-enos para inhibir trastornos patologicos MXPA97001529A (es)

Applications Claiming Priority (12)

Application Number Priority Date Filing Date Title
US012410 1987-02-09
US012404 1987-02-09
US1241196P 1996-02-28 1996-02-28
US1240196P 1996-02-28 1996-02-28
US1240296P 1996-02-28 1996-02-28
US1240396P 1996-02-28 1996-02-28
US1241096P 1996-02-28 1996-02-28
US1240496P 1996-02-28 1996-02-28
US012402 1996-02-28
US012403 1996-02-28
US012401 1996-02-28
US012411 1996-02-28

Publications (2)

Publication Number Publication Date
MX9701529A true MX9701529A (es) 1998-06-28
MXPA97001529A MXPA97001529A (es) 1998-10-30

Family

ID=

Also Published As

Publication number Publication date
AU1495697A (en) 1997-09-04
EP0792640A3 (en) 1998-07-08
AU707455B2 (en) 1999-07-08
CN1165651A (zh) 1997-11-26
KR970061247A (ko) 1997-09-12
IL120268A0 (en) 1997-06-10
JPH09328421A (ja) 1997-12-22
CA2198571A1 (en) 1997-08-28
EP0792640A2 (en) 1997-09-03

Similar Documents

Publication Publication Date Title
MY132056A (en) Methods of inhibiting physiological conditions associated with an excess of neuropeptide y.
FI925342A0 (fi) Menetelmä terapeuttisesti aktiivisen (+)- -(2,3-dimetoksifenyyli)-1-/2-(4-fluorifenyyli)etyyli/-4-piperidiinimetanolin valmistamiseksi
MY115662A (en) Novel compounds with analgesic effect
MX9803809A (es) Inhibidores de hidroxamato de bifenilo de metaloproteinasas de matriz.
MY119375A (en) Treatment of tinnitus using neuroprotective agents
CA2289717A1 (en) Novel therapy for constipation
RU94044436A (ru) Способы подавления атрофии кожи и влагалища
UA41355C2 (uk) Засіб для лікування нейро-сніду
BG105534A (en) 5ht1 means and method for the treatment of migraine
GEP20043383B (en) Cell Adhesion-Inhibiting Antiinflammatory and Immune-Suppressive Compounds
ZA948031B (en) Methods of inhibiting uterine fibroses
RU94044453A (ru) Применение 2-фенил-3-ароилбензотиофенов для ингибирования себореи и угрей
ZA967880B (en) Compositions and methods for inhibition of the patho-physiologic actions in mammals in tumor necrosis facto-alpha
RU94037233A (ru) Применение 2-фенил-3-ароилбензотиофенов для лечения лекарственноустойчивых новообразований
CA2198580A1 (en) Combination therapy to treat osteoporosis
MX9709466A (es) Medicamento para inhibir el melanoma.
CA2289017A1 (en) The use of a nitroxide or a prodrug thereof in the prophylactic and therapeutic treatment of cancer
NO984920D0 (no) Sammensetninger omfattende en nitroneforbindelse for anvendelse ved behandling av okulµr inflammasjon
MY126321A (en) Use of (alpha)-adrenoreceptor antagonists in the prevention and treatment of cancer.
MX9701529A (es) Uso de (e)-1-[4'-(2-alquilaminoetoxi)fenil]-1-(3'-hidroxifenil)-2-f enilbut-1-enos para inhibir trastornos patologicos.
MX9701333A (es) Metodos para inhibir el daño neuronal.
MX9701606A (es) Terapia de combinacion para evitar la perdida osea-progesterona y agonistas de estrogeno.
RU94044457A (ru) Применение бензтиофенов для ингибирования гирсутизма и алопеции у женщин
WO2000002877A3 (en) New pharmaceutically active compounds
MY113406A (en) Methods of inhibiting physiological conditions associated with an excess of bradykinin